In this derivation–validation study of patients who underwent LT for HCC, we have shown, both in the training and in the validation cohorts, that endothelial expression of angiopoietin-2 assessed at explant was able to strongly and independently predict HCC recurrence and mortality after LT. This evidence concerns the gene ANGPT2 and hepatocellular carcinoma.